|
Responders at 24 weeks
(HbA1c < 7% or ≥ 1% reduction) n = 1188
|
Nonresponders at 24 Weeks
(HbA1c ≥ 7% and < 1% reduction)
n = 297
|
P value
|
---|
Age, years
|
57.8 (9.9)
|
57.2 (10.1)
|
0.323
|
Age group
| | |
0.833
|
< 65 years
|
893 (75.2)
|
225 (75.8)
| |
≥ 65 years
|
295 (24.8)
|
72 (24.2)
|
Gender
| | |
0.012
|
Women
|
543 (45.7)
|
160 (53.9)
| |
Men
|
645 (54.3)
|
137 (46.1)
| |
Duration of T2DM, years
|
10.3 (6.6)
|
9.7 (6.5)
|
0.159
|
Weight, kg
|
87.5 (19.7)
|
85.8 (21.6)
|
0.201
|
BMI, kg/m2
|
31.3 (5.70)
|
30.9 (5.70)
|
0.213
|
HbA1c, %
|
9.1 (1.2)
|
8.3 (0.9)
|
< 0.001
|
HbA1c, mmol/mol
|
99 (13)
|
91 (10)
|
< 0.001
|
FBG, mg/dL
|
186.7 (52.0)
|
158.5 (42.2)
|
< 0.001
|
≥ 1 OAMs Targeting PPGa
|
1111 (93.5)
|
290 (97.6)
|
0.006
|
SU, yes
|
1067 (89.8)
|
284 (95.6)
|
0.002
|
2 OAMs
|
790 (66.5)
|
194 (65.3)
|
0.701
|
MET/SU
|
614 (51.7)
|
167 (56.2)
|
–
|
3 OAMs
|
389 (32.7)
|
100 (33.7)
|
0.761
|
MET/SU/TZD
|
346 (29.1)
|
89 (30.0)
|
–
|
4 OAMs
|
7 (0.6)
|
3 (1.0)
|
0.429
|
- Individual participant data were pooled from 3 randomized clinical trials [20,21,22] and are mean (SD) or n (%). Patients are those who were randomized to insulin glargine as the only insulin treatment and with no missing HbA1c values at 24 weeks. Two-sided P values were considered statistically significant if < 0.05 and were calculated by ANOVA model (response = subgroup) for continuous variables and by Pearson’s Chi-square or Fisher’s exact (for OAM data with less than 80% of cells with an expected value ≥5) test for categorical variables. Abbreviations: AGI alpha glucosidase inhibitor, BMI body mass index, DPP-IV dipeptidyl peptidase IV, FBG fasting blood glucose, HbA1c glycated hemoglobin, MEG meglitinides, MET metformin, OAM oral antihyperglycemic medication, PPG postprandial blood glucose, SD standard deviation, SU sulphonylurea, T2DM type 2 diabetes mellitus, TZD thiazolidinedione. aOAMs targeting postprandial glucose were SU, DPP-IV, AGI, and MEG